Clinical trial
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
NCT05563272
Study timeline
Study start (actual)2023-06-06Date precision: day
Registry last updated2025-07-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Cervical Cancerunresolved
Colorectal Cancerunresolved
Esophageal Cancerunresolved
Gastric Cancerunresolved
Glioblastoma Multiformeunresolved
Cholangiocarcinomaunresolved
Hepatocellular Carcinomaunresolved
Head and Neck Squamous Cell Carcinomaunresolved
Nasopharyngeal Carcinomaunresolved
Non Small Cell Lung Cancerunresolved
Small Cell Lung Cancerunresolved
Epithelial Ovarian Cancerunresolved
Pancreatic Ductal Adenocarcinomaunresolved
Soft Tissue Sarcomaunresolved
Gastric Adenocarcinomaunresolved
Malignant Mesothelioma (MM)unresolved
Von Hippel Lindauunresolved
Bladder Cancerunresolved
Bladder Urothelial Carcinomaunresolved
Interventions
89Zr-girentuximab for PET/CT imaging of CAIX positive tumorsDIAGNOSTIC_TEST
Sponsors & collaborators
Telix Pharmaceuticals (Innovations) Pty Ltdlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05563272 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.